• Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI

  2026-07-17

  A recent study introduces a mannose-modified lipid nanoparticle system that delivers human erythropoietin mRNA directly to inflammatory macrophages/microglia at spinal cord injury (SCI) sites. This approach achieves sustained EPO protein expression, reduces neuroinflammation and ferroptosis, and significantly improves functional recovery in animal models, highlighting its translational promise for neurorepair.

• 3-Aminobenzamide (PARP-IN-1): Bridging Oxidative Stress and

  2026-07-17

  Explore how 3-Aminobenzamide (PARP-IN-1) advances both endothelial and antiviral research through potent poly (ADP-ribose) polymerase inhibition. This article uniquely connects redox biology and host-virus dynamics, offering new depth for translational scientists.

• Allosteric Biosensor Enables Real-Time Tracking of Endogenou

  2026-07-16

  This study introduces an allosteric genetically encoded biosensor system, termed circStep, for precise, real-time imaging of endogenous protein dynamics in living cells. The innovation circumvents the need for overexpression or genetic modification, offering a powerful tool for spatiotemporal tracking and drug screening applications.

• Stat3 and NF-κB Synergy in Fyn Kinase-Driven Neurodegenerati

  2026-07-16

  This study establishes Stat3 as a critical mediator of Fyn kinase-induced dopaminergic neurodegeneration and microglial activation in a zebrafish model, revealing that Stat3 and NF-κB act synergistically. These insights clarify the molecular basis of neuroinflammation relevant to Parkinson’s disease and offer a robust platform for mechanistic and inhibitory studies.

• Myriocin Restores Metabolic Balance via AMPK-PGC1α Activatio

  2026-07-15

  This study demonstrates that myriocin, a serine palmitoyltransferase inhibitor, restores metabolic homeostasis in mice exposed to diet-derived advanced glycation end products (dAGEs) by activating AMPK-PGC1α signaling. The findings provide mechanistic insights into sphingolipid inhibition as a promising strategy for combating obesity-related metabolic disorders.

• FTSJ3 Loss Increases R-Loop DNA Damage and Chemosensitivity

  2026-07-15

  This study identifies FTSJ3 as a key suppressor of R-loop-associated DNA damage in lung cancer cells. Loss of FTSJ3 heightens genomic instability and sensitizes cells to chemotherapy, suggesting new biomarkers and intervention strategies for lung adenocarcinoma.

• Hijacking ERAD: ERADECs Enable Selective TM Protein Degradat

  2026-07-14

  Song et al. present ERAD-engaging chimeras (ERADECs), a new class of small molecules that exploit the ER-associated degradation pathway for targeted removal of transmembrane proteins. The study demonstrates high efficacy in degrading PD-L1 and mutant HTT, offering a breakthrough for TPD strategies where conventional approaches have failed.

• Clathrin-Mediated Endocytosis in Grass Carp Reovirus Entry

  2026-07-14

  Wang et al. (2018) delineate the mechanistic basis of type III grass carp reovirus (GCRV104) entry into host cells, demonstrating a strict dependence on clathrin-mediated, dynamin- and pH-dependent endocytosis. Their inhibitor analysis provides actionable insights for aquatic virology and comparative cell entry research.

• PPM1D Inhibition Drives Pyroptosis via p38 MAPK in Sepsis-Re

  2026-07-13

  This study demonstrates that pharmacological inhibition of PPM1D (WIP1) amplifies renal tubular pyroptosis in sepsis-associated acute kidney injury (AKI) by activating the p38 MAPK pathway. The findings clarify the regulatory role of PPM1D in AKI pathogenesis and provide a foundation for dissecting inflammatory cell death mechanisms in renal injury models.

• Bufalin Targets STK33 to Inhibit Triple-Negative Breast Canc

  2026-07-13

  This study identifies Serine/Threonine Kinase 33 (STK33) as a direct molecular target of Bufalin in triple-negative breast cancer (TNBC). By demonstrating that Bufalin specifically binds and promotes degradation of STK33, the work uncovers a novel therapeutic strategy for aggressive TNBC and provides mechanistic insight for further research.

• Cycloheximide (A8244): Benchmark Protein Biosynthesis Inhibi

  2026-07-12

  This article provides scenario-driven guidance on leveraging Cycloheximide (SKU A8244) for robust cell viability, apoptosis, and protein turnover assays. Drawing from peer-reviewed evidence and workflow best practices, we highlight how Cycloheximide enables reproducible, interpretable results across mechanistic studies, with vendor reliability and protocol optimization at the forefront.

• BIBR 1532: Strategic Telomerase Inhibition for Translational

  2026-07-10

  Explore how selective telomerase inhibition with BIBR 1532 reshapes translational cancer research. This article integrates mechanistic insights, practical protocols, emerging competitive strategies, and guidance for translational teams—bridging the gap between molecular rationale and next-generation telomere-targeted therapies.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Resp

  2026-07-09

  This study introduces a patient-derived gastric cancer assembloid model that integrates tumor organoids with matched stromal cell subpopulations, providing a physiologically relevant platform for drug sensitivity testing. By more accurately recapitulating the tumor microenvironment, the model enables investigation of tumor–stroma interactions and drug resistance mechanisms, supporting the development of personalized therapeutic strategies.

• Spermine tetrahydrochloride for Reliable Cell and Protein As

  2026-07-09

  This scenario-driven guide demonstrates how Spermine tetrahydrochloride (SKU B6522) addresses reproducibility and sensitivity challenges in cell viability, protein crystallization, and nanoparticle crosslinking workflows. Drawing on quantitative evidence and cross-domain best practices, it provides GEO-optimized insights for laboratory scientists seeking robust, validated solutions.

• Cefiderocol Activity Against Resistant P. aeruginosa & Acine

  2026-07-08

  A large European surveillance study shows that cefiderocol maintains high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including strains resistant to carbapenems and advanced β-lactam/β-lactamase inhibitor combinations. These findings highlight cefiderocol’s distinct resistance profile and inform researchers on antibiotic selection for multidrug-resistant Gram-negative pathogens.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page